1. Which best describes your professional Training? (multiple options possible)
   ○ Nuclear Medicine Physician
   ○ Nuclear Medicine Technologist
   ○ Nuclear Medicine Scientist or Researcher
   ○ Nuclear Medicine Chemist/Pharmacist
   ○ Nuclear Medicine Physicist
   ○ Radiologist
   ○ Nuclear Medicine Resident or Fellow
   ○ Other

2. Which of the following best describes your practice?
   ○ Private Practice, mainly outpatient
   ○ University Hospital
   ○ Non University Hospital
   ○ Private Multispecialty Office
   ○ Industry
   ○ Other

3. Do you treat patients with lymphoma with Bexxar or Zevalin Radioimmunotherapy?
   ○ No
   ○ Yes, 1 - 3 in the last 24 months
   ○ Yes, 4 - 7 in the last 24 months
   ○ Yes, 8 - 15 in the last 24 months
   ○ Yes, > 15 in the last 24 months

4. Which Radioimmunotherapy Agent for Non Hodgkins Lymphoma do you use?
   ○ Bexxar
   ○ Zevalin
   ○ Both
   ○ Neither

5. Who refers patients with Non-Hodgkins Lymphoma to you for Bexxar or Zevalin? (multiple options possible)
   ○ Physicians from University Hospitals
   ○ Physicians from non University Hospitals
   ○ Physicians from multispecialty offices
   ○ Physicians from private offices
   ○ Patients do refer themselves
   ○ No one in the past 24 months

6. Lymphoma treatment with Bexxar or Zevalin: When should it be used? (multiple options possible)
   ○ 1st line treatment for Non Hodgkins Lymphoma
   ○ 2nd line treatment for Non Hodgkins Lymphoma
   ○ 3rd line treatment for Non Hodgkins Lymphoma
   ○ Later than 3rd line treatment for Non Hodgkins Lymphoma
   ○ Consolidation after chemoimmunotherapy in Non Hodgkins Lymphoma
   ○ Only investigational for Non Hodgkins Lymphoma
   ○ Never
   ○ In Follicular or Secondary Transformed Non Hodgkins Lymphoma
   ○ In all CD20 positive Non Hodgkins Lymphoma
   ○ Other
7. If you treat with Bexxar or Zevalin: Do you treat in an inpatient or outpatient setting?
   ○ Inpatient
   ○ Outpatient
   ○ Both

8. Do you treat thyroid diseases with radioactive iodine?
   ○ Yes
   ○ No

9. Do Radiation Oncologists treat with unsealed sources at your institution?
   ○ Yes
   ○ No
   ○ Don't know

10. Does your Institution accept Medicare patients for treatment with Bexxar or Zevalin?
    ○ Yes
    ○ No
    ○ Don't know

11. Non Hodgkins Lymphoma treatment with Bexxar or Zevalin: What are your concerns?

<table>
<thead>
<tr>
<th>Concern</th>
<th>1 (no concern)</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4 (major concern)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zevalin or Bexxar therapy provides poor payment for the time and effort</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>Zevalin or Bexxar therapy provides poor payment for the time and</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>effort in the radiolabelling process</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bexxar or Zevalin take too much time from my practice in general</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>We have concerns about the Radiation Safety</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>We have concerns about the Dosimetry Procedure</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>Bexxar administration is too complicated in general</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>Zevalin administration is too complicated in general</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>Most Nuclear Physicians are not trained to administer myeloablative</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>therapies like Zevalin or Bexxar</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncologists/Hematologists prefer to treat by themselves with</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>non-radioactive compounds</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bexxar or Zevalin Treatment is too expensive</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>Bexxar or Zevalin Treatment does not have enough reported randomized</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>There might be unexpected late side effects of Bexxar or Zevalin (MDS)</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>Concerns exist that subsequent treatments will not be possible after</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>Bexxar or Zevalin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

12. Do you believe Radioimmunotherapy for the Treatment of Non-Hodgkins Lymphoma will grow in importance?
    ○ It will grow in importance
    ○ It will probably grow in importance
    ○ uncertain
    ○ It will probably NOT grow in importance
    ○ It will NOT grow in importance
13. Do you have any further concerns or comments pertaining to Non Hodgkins Lymphoma Treatment with Bexxar or Zevalin?

____________________________________________

____________________________________________

____________________________________________

____________________________________________